ARCA and Medtronic, Inc. (NYSE: MDT) have entered into a collaboration to support GENETIC-AF, ARCA’s Phase 2B clinical trial evaluating Gencaro as a potential treatment for atrial fibrillation. In April 2018, Medtronic, Inc. and ARCA agreed to extend their U.S., Canadian and European Clinical Trial Collaboration Agreement for one additional year. Medtronic uses its proprietary CareLink System to collect and analyze the cardiac rhythm data from the implanted Medtronic devices of a substudy of patients participating in GENETIC-AF. Medtronic is the world’s largest medical technology company and a leader in medical technologies to improve the treatment of chronic diseases, including cardiac rhythm disorders. www.medtronic.com
ARCA and Laboratory Corporation of America (NYSE: LH) have jointly developed the companion diagnostic for Gencaro. LabCorp is providing the companion diagnostic test and testing services to support GENETIC-AF. LabCorp is the world’s leading healthcare diagnostics company. www.labcorp.com
ARCA’s founding scientists are affiliated with the University of Colorado, and important biotechnology that is under development by ARCA had its origins in University laboratories. ARCA is proud of its longstanding partnership and licensing agreement with the University.
ARCA biopharma is dedicated to establishing mutually beneficial long-term relationships with our partners to improve the health of cardiovascular patients around the world. Our partnering strategy for Gencaro is focused on development and commercialization collaborations in which we retain U.S. commercial and/or co-promotion rights. We are also actively seeking in-licensing opportunities involving clinical stage therapeutics addressing cardiovascular diseases.
Please contact: Chris Ozeroff at email@example.com for business development and partnering inquiries.